{"id":2529,"date":"2024-01-15T19:28:08","date_gmt":"2024-01-16T00:28:08","guid":{"rendered":"https:\/\/cqdm.org\/en\/news-and-events\/research-and-development-of-an-antimetastatic-peptide-conjugate-of-docetaxel-th1902-against-sortilin-positive-cancers\/"},"modified":"2024-09-25T16:24:23","modified_gmt":"2024-09-25T20:24:23","slug":"research-and-development-of-an-antimetastatic-peptide-conjugate-of-docetaxel-th1902-against-sortilin-positive-cancers","status":"publish","type":"post","link":"https:\/\/cqdm.org\/en\/news-and-events\/research-and-development-of-an-antimetastatic-peptide-conjugate-of-docetaxel-th1902-against-sortilin-positive-cancers\/","title":{"rendered":"Research and development of an antimetastatic peptide conjugate of docetaxel (TH1902) against sortilin positive cancers"},"content":{"rendered":"\n<p><strong>Challenge:<\/strong>&nbsp;Cancers with metastases are responsible for 90% of cancer deaths. Unfortunately, metastases often become refractory to treatment and although certain molecules are theoretically able to act on these tumors, their non-targeted administration greatly limits their effectiveness.<\/p>\n\n\n\n<p><strong>Solution:&nbsp;<\/strong>This project aims to validate the efficacy of the peptide-drug (TH1902) on secondary tumors by characterizing its mechanisms of action in&nbsp;<em>vitro<\/em>&nbsp;and&nbsp;<em>in vivo<\/em>&nbsp;models of cancer metastasis, and by analyzing its pharmacokinetics and stability in biological fluids. The research team will also verify that TH1902 is functional in several types of metastatic cancers.<\/p>\n\n\n\n<p><strong>Expected Achievements \/Impacts:&nbsp;<\/strong>Overall, the resulting data will support and better define future clinical trials in patients with sortilin-positive metastatic cancers and to further explore the potential combination of its compound with other therapeutic drugs. The identification of new treatment options for patients with overexpression of the sortilin receptor offers tremendous hope, particularly for tumors that are refractory to available anti-cancer treatments.<\/p>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table><tbody><tr><td><strong>Principal Investigator :<\/strong><a href=\"https:\/\/cqdm.orgwp-content\/uploads\/2023\/12\/Borhane-Annabi.png\"><\/a><br><strong>Borhane Annabi<br><\/strong>UQAM<\/td><\/tr><tr><td><strong>Co-Investigators&nbsp;:&nbsp;<\/strong>N\/A<\/td><\/tr><tr><td><strong>Project of<br>$1,590,000 over&nbsp;2,5 years<\/strong><\/td><\/tr><tr><td><strong>Supported by CQDM through :<br><\/strong>\u2013 Minist\u00e8re de l\u2019\u00c9conomie, de l\u2019Innovation et de l\u2019\u00c9nergie du Qu\u00e9bec (MEIE)<\/td><\/tr><tr><td><strong>And by co-funding partners :<br><\/strong>\u2013 Theratechnologies<br>\u2013 Quebec Breast Cancer Foundation<br>\u2013 Mitacs<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Challenge:&nbsp;Cancers with metastases are responsible for 90% of cancer deaths. Unfortunately, metastases often become refractory to treatment and although certain molecules are theoretically able to act on these tumors, their non-targeted administration greatly limits their effectiveness. Solution:&nbsp;This project aims to validate the efficacy of the peptide-drug (TH1902) on secondary tumors by characterizing its mechanisms of&hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2529","post","type-post","status-publish","format-standard","hentry","category-our-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/comments?post=2529"}],"version-history":[{"count":1,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2529\/revisions"}],"predecessor-version":[{"id":4734,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2529\/revisions\/4734"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=2529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/categories?post=2529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/tags?post=2529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}